| Net sales | 919.83M |
| Cost of sales | 588.46M |
| Gross profit | 331.36M |
| Operating expenses | |
| Distribution | |
| Research and development | 28.53M |
| Selling and administration | 111.66M |
| Subtotal | 152.76M |
| Write-off of in-process research and development | |
| Restructuring | 0 |
| Total | |
| Operating income | 178.61M |
| Interest, net | |
| Other (income) expense, net | 841K |
| Investment impairment | |
| Income from continuing operations before income taxes | 160.09M |
| Income tax expense | 48.16M |
| Income from continuing operations | |
| Income (loss) from discontinued operations, net of tax | |
| Net income | 111.92M |
| Basic | |
| Continuing operations | |
| Discontinued operations | |
| Basic earnings per share | 1.19 |
| Diluted | |
| Continuing operations | |
| Discontinued operations | |
| Diluted earnings per share | 1.18 |
| Weighted average shares outstanding | |
| Basic | 93.99M |
| Diluted | 94.52M |
| Dividends declared per share | 0.09 |